Rein Therapeutics (RNTX) Non-Current Assets (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Non-Current Assets of $20.8 million for Q1 2026, down 57.74% year-over-year from $49.3 million in Q1 2025, and up 5.06% quarter-over-quarter from $19.8 million in Q4 2025.
Rein Therapeutics (RNTX) Non-Current Assets (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Non-Current Assets for 11 consecutive years, with $20.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 57.74% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $140.1 million (down 48.04% YoY), while the FY2025 annual figure was $19.8 million, down 59.14% from the prior year.
- Non-Current Assets improved to $20.8 million in Q1 2026 per RNTX's latest filing, from $19.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $87.7 million in Q4 2023 and bottomed at $29000.0 in Q3 2023.
- Historically, Non-Current Assets has averaged $34.4 million across 5 years, with a median of $20.8 million in 2026.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 83.71% — and 2024, when it jumped 294841.38%.
- Rein Therapeutics' Non-Current Assets stood at $134000.0 in 2022, then soared by 65379.1% to $87.7 million in 2023, then slumped by 44.69% to $48.5 million in 2024, then sank by 59.14% to $19.8 million in 2025, then rose by 5.06% to $20.8 million in 2026.
- Business Quant data shows RNTX's Non-Current Assets at $20.8 million in Q1 2026, $19.8 million in Q4 2025, and $48.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 24.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.52 Mn |
| Mar 31, 2026 | 20.84 Mn |
| Dec 31, 2025 | 19.83 Mn |
| Sep 30, 2025 | 48.53 Mn |
| Jun 30, 2025 | 50.88 Mn |
| Mar 31, 2025 | 49.30 Mn |
| Dec 31, 2024 | 48.53 Mn |
| Sep 30, 2024 | 85.53 Mn |
| Jun 30, 2024 | 86.24 Mn |
| Mar 31, 2024 | 86.43 Mn |
| Dec 31, 2023 | 87.74 Mn |
| Sep 30, 2023 | 29,000.00 |
| Jun 30, 2023 | 39,000.00 |
| Mar 31, 2023 | 52,000.00 |
| Dec 31, 2022 | 134,000.00 |
| Sep 30, 2022 | 178,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Mar 31, 2022 | 262,000.00 |
| Dec 31, 2021 | 304,000.00 |
| Sep 30, 2021 | 345,000.00 |